CRISPR Therapeutics Ltd
CRSP
ISIN CH0334081137 / Valor 33408113
CRISPR Therapeutics Ltd
UMushroom community rating:
About company
CRISPR Therapeutics Ltd is a biotechnology company that focuses on developing gene-editing therapies. One of their key products is CASGEVY™, a CRISPR/Cas9 gene-edited therapy developed in collaboration with Vertex Pharmaceuticals Incorporated, which has received approval in some countries for treating patients with sickle cell disease or transfusion-dependent beta thalassemia. The company's innovative approach to gene editing has the potential to revolutionize the treatment of genetic diseases, offering hope to patients with previously untreatable conditions.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
5181 M
Market cap (USD)
1,280,714
Daily traded volume (Shares)
39.67 / 38.21
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Shayaan Haider
Fabio Kull
Mark Hernandez
EQUITIES OF THE SAME SECTOR
